Last reviewed: November 16, 2025 Last reviewed: November 16, 2025 Comirnaty (Pfizer-BioNTech) mRNA COVID-19 vaccine is FDA-licensed for use in ages 5 years through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older mNexspike (Moderna) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Nuvaxovid (Sanofi-Novavax) is FDA-licensed for use in ages 12 through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Spikevax (Moderna) mRNA COVID-19 vaccine is FDA-licensed for use in ages 6 months through 64 years with at least one underlying condition that puts them at risk for severe COVID-19 infection and individuals 65 years and older Although the FDA licenses are limited in the age group younger than 65 years to those with underlying conditions that put them at risk for severe COVID-19 infection, the ACIP has recommended use based on individual decision-making (i.e., shared clinical decision-making) for all people age 6 months and older

Shown in Figure 3H, SLC7A11 expression was reduced in atherosclerotic lesions as compared with nondiseased specimens
Cardiac copper concentration gradually decreases after ischemic injury and is positively correlated with HIF-1-mediated expression of angiogenic and glycolytic genes [48]
What are the main side effects of tesofensine in clinical trials
Simply skip that day and resume on the next night as scheduled
This campaign was not possible without tireless efforts among former and current UGA SNAP-Ed staff and grad students (including Darci Bell, Sierra Woodruff, and Claire Hawkins)